Immage Biotherapeutics Corp. (IMMG) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerImmage Biotherapeutics Corp. (IMMG) trades at $0.0001. Immage Biotherapeutics Corp. is a financial services company that was formerly engaged in developing immunotherapy biologics. Sector: Financials.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for IMMG: IMMG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Immage Biotherapeutics Corp. (IMMG) Financial Services Profile
Immage Biotherapeutics Corp., operating within the financial services sector, previously focused on developing immunotherapy biologics. Currently a subsidiary of Coventry International Limited, the company has minimal business operations and a market capitalization of $0.00B, reflecting its transitional state and high-risk profile within the financial conglomerates landscape.
What Is the Investment Thesis for IMMG?
Investing in Immage Biotherapeutics Corp. presents a highly speculative opportunity given its current lack of significant business operations and its history of transitioning from a biotechnology focus. Key considerations include the potential for future strategic shifts under its parent company, Coventry International Limited. The company's high beta of 32.51 indicates extreme volatility. The absence of a dividend further underscores the speculative nature of this investment. Investors should closely monitor any announcements regarding future business plans or restructuring initiatives, as these will be critical value drivers. The company's P/E ratio is -0.07.
Based on FMP financials and quantitative analysis
IMMG Key Highlights
Market capitalization of $0.00B, indicating a micro-cap valuation.
- P/E ratio of -0.07, reflecting current losses or minimal earnings.
- Beta of 32.51, indicating extremely high volatility compared to the market.
- No dividend yield, suggesting that the company does not currently distribute profits to shareholders.
- Currently has no significant business operations, marking a critical transition period.
Who Are IMMG's Competitors?
IMMG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIVX CTR Investments & Consulting, Inc. | $0.19 | +90.00% | $26.6M | — |
| XXI Twenty One Capital Inc | $6.60 | -2.22% | $68.0M | 39 5-pillar |
| CHPG ChampionsGate Acquisition Corporation | $10.48 | +0.10% | $105M | 50 5-pillar |
| HVII Hennessy Capital Investment Corp. VII | $4.46 | -50.88% | $116M | 43 5-pillar |
| ACOG Alpha Cognition Inc. | $9.10 | +4.60% | $141M | — |
| TDWD Tailwind 2.0 Acquisition Corp. | $10.15 | +0.10% | $152M | 52 5-pillar |
| ETHM Dynamix Corp | $10.90 | -0.05% | $181M | 71 5-pillar |
| RILY BRC Group Holdings, Inc. | $4.86 | -3.67% | $195M | 65 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IMMG's Key Strengths?
Subsidiary of Coventry International Limited, providing potential access to resources and capital.
- Previously engaged in biotechnology research, indicating some level of scientific expertise.
- Established corporate structure and history dating back to 2012.
What Are IMMG's Weaknesses?
Lack of significant business operations, resulting in minimal revenue generation.
- Small number of employees (3), limiting operational capacity.
- High beta of 32.51, indicating extreme volatility and risk.
- Uncertain strategic direction and dependence on decisions made by its parent company.
What Are the Key Risks for IMMG?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Intense competition within the financial conglomerates sector.
- Regulatory changes and compliance requirements.
- Economic cycles and market volatility.
- Dependence on the strategic decisions and financial support of Coventry International Limited.
- Limited financial disclosure and transparency due to OTC Other listing.
What Are IMMG's Competitive Advantages?
- Currently, Immage Biotherapeutics Corp. does not possess a discernible moat due to its lack of significant business operations.
- Historically, its potential moat could have been based on proprietary immunotherapy technologies, but this is no longer applicable.
- Future competitive advantages will depend on strategic decisions made by Coventry International Limited and any new ventures the company pursues.
What Does IMMG Do?
Immage Biotherapeutics Corp., founded in 2012 and headquartered in Bethesda, Maryland, initially operated under the name Epicure Charcoal, Inc. before rebranding in June 2015. The company's original focus was on developing novel immunotherapy biologics aimed at treating various cancers within the United States. However, as of the current date, Immage Biotherapeutics Corp. does not have significant business operations. The company functions as a subsidiary of Coventry International Limited. With a small team of three employees, the company's activities are limited. Its transition from a biotechnology focus to its current state reflects a significant shift in its operational direction. The company's market capitalization is $0.00B, and it trades on the OTC market.
What Products and Services Does IMMG Offer?
- Formerly engaged in developing novel immunotherapy biologics for cancer treatment.
- Currently operates as a subsidiary of Coventry International Limited.
- Maintains a corporate presence in Bethesda, Maryland.
- Has a small team of three employees.
- Focuses on financial services, although its specific activities are limited.
- Underwent a name change from Epicure Charcoal, Inc. in 2015.
How Does IMMG Make Money?
- Currently, the business model is not operational due to the lack of significant business activities.
- Previously focused on developing and commercializing immunotherapy biologics.
- Functions as a subsidiary, potentially receiving funding or strategic direction from Coventry International Limited.
What Industry Does IMMG Operate In?
Immage Biotherapeutics Corp. operates within the financial conglomerates sector, a segment characterized by diverse business activities and complex organizational structures. The broader financial services industry is subject to regulatory changes, economic cycles, and technological advancements. Given Immage Biotherapeutics Corp.'s current state of minimal operations, its positioning within this landscape is highly dependent on strategic decisions made by its parent company, Coventry International Limited. Competition within the financial conglomerates sector is intense, with established players like AXTG and BITCF.
Who Are IMMG's Key Customers?
- Historically, potential customers included patients and healthcare providers in the oncology space.
- Currently, the primary customer is Coventry International Limited, its parent company.
- Future customers will depend on the company's strategic direction and any new ventures it undertakes.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Immage Biotherapeutics Corp. operates in the Financial - Conglomerates industry within the Financial Services sector. It is headquartered in Bethesda, US. The company is led by CEO Zhi Cong Mou. IMMG has traded publicly since 2022.
Key Financial Metrics
Return on assets is -89.0%, showing how much profit it generates from its asset base. A current ratio of 3.67 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Immage Biotherapeutics Corp.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
IMMG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
IMMG Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Oct 4, 2019
IMMG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IMMG.
Price Targets
Wall Street price target analysis for IMMG.
IMMG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IMMG; grades run from A+ (80-100) to F (below 30).
Leadership: Zhi Cong Mou
Unknown
Zhi Cong Mou currently manages three employees at Immage Biotherapeutics Corp. His leadership is pivotal in navigating the company's transition and potential future ventures, given its current state of minimal operations.
Track Record: Due to the limited business operations of Immage Biotherapeutics Corp., Zhi Cong Mou's track record is difficult to assess. His strategic decisions will be critical in determining the company's future direction and success. There is no available information regarding key achievements or company milestones under his leadership.
IMMG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Immage Biotherapeutics Corp. may not meet the minimum financial standards required for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited financial disclosure and may be subject to greater risks compared to those listed on national exchanges like NYSE or NASDAQ. This tier is generally reserved for companies with distressed financials, penny stocks, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The unknown disclosure status increases the risk due to a lack of transparency.
- Low Liquidity: The OTC Other listing and minimal operations suggest very low trading volume and wide bid-ask spreads.
- Speculative Nature: The absence of significant business operations makes the investment highly speculative.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight compared to exchange-listed companies.
- Potential for Delisting: Failure to meet minimum listing requirements could result in delisting from the OTC market.
- Verify the company's financial disclosure status and obtain access to any available financial reports.
- Assess the company's management team and their experience in the financial services sector.
- Evaluate the company's strategic plans and potential for future growth.
- Review the company's legal and regulatory compliance status.
- Analyze the company's capital structure and any outstanding debt obligations.
- Monitor trading volume and bid-ask spreads to assess liquidity.
- Understand the ownership structure and any potential conflicts of interest.
- Subsidiary of Coventry International Limited: This affiliation provides some level of oversight and potential financial support.
- Established Corporate History: The company has been in existence since 2012, indicating some level of organizational stability.
- Corporate Headquarters: The company maintains a physical presence in Bethesda, Maryland.
- Name Change: The company changed its name in 2015 to Immage Biotherapeutics Corp.
IMMG Financials Stock FAQ
What do analysts say about IMMG stock?
Given the company's lack of significant business operations and OTC Other listing, there is limited analyst coverage of IMMG stock. Key valuation metrics such as revenue and earnings are not applicable due to the company's current state.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company's financial performance and future prospects are highly uncertain due to its lack of significant business operations.
- Investment in micro-cap OTC stocks carries significant risks.